XT
PRLD icon

XTX Topco’s Prelude Therapeutics PRLD Stock Holding History

XTX Topco’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Buy
57,190
+7,031
+14% +$18.4K ﹤0.01% 2849
2025
Q4 		$145K Buy
50,159
+34,581
+222% +$58.4K ﹤0.01% 2521
2025
Q3 		$22.4K Sell
15,578
-26,995
-63% -$27.1K ﹤0.01% 2305
2025
Q2 		$34.5K Buy
42,573
+17,873
+72% +$15.5K ﹤0.01% 2079
2025
Q1 		$19K Sell
24,700
-13,639
-36% -$12.7K ﹤0.01% 2147
2024
Q4 		$48.9K Sell
38,339
-9,900
-21% -$13.1K ﹤0.01% 1900
2024
Q3 		$99.9K Buy
+48,239
New +$223K 0.01% 1609

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

XTX Topco's PRLD Position: Q1 2026 in Review

XTX Topco increased its Prelude Therapeutics (PRLD) stake by 14% in Q1 2026, buying an estimated $18.4K and bringing the position to 57,190 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #2849.

XTX Topco first reported a position in PRLD in Q3 2024 and has held it in 7 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • XTX Topco held 57,190 shares of Prelude Therapeutics worth $196K as of Q1 2026.
  • XTX Topco bought 7,031 Prelude Therapeutics shares in Q1 2026, an estimated $18.4K.
  • Prelude Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2849 holding.
  • XTX Topco first reported a position in Prelude Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.